Novo Rapid Insulin
Impaired Glucose Tolerance
Hadassah Medical OrganizationN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
46 Active assets in the Impaired Glucose Tolerance cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Yu Chen | Phase 4 | A |
Liraglutide Woman's | Phase 4 | BBB |
Exenatide RenJi Hospital | Phase 4 | BBB |
Semaglutide Esbjerg Hospital - University Hospital of Southern Denmark | Phase 4 | BBB |
Semaglutide The University of Texas Health Science Center at San Antonio | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Novo Rapid Insulin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →